The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular w...
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
De Gruyter
2022-01-01
|
| سلاسل: | Open Medicine |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1515/med-2021-0374 |